| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Hinge Health, Inc.$74.71
-0.4 (-0.53%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
2.79 B
EPS
-5.44
P/E Ratio
-6.5 $
Value Trade
58.24 M
SEC Financials
Q1 2026Dilution Risk
Revenue
182.31 M
R&D Expenses
30.34 M
Operating CF
43.08 M
Total Assets
728.77 M
Total Liabilities
417.21 M
Equity
111.69 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
315.87 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.13 M
52 Week Range
30.08 - 62.18
% held by Insiders
57.88 %
% held by Institutions
55.99 %
Enterprise Value
2.63 B
Total Shares
54.65 M
Short %
15.19 %
Float Shares
41.04 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 16%
Small Cap (rank 768 of 913)
Percentile RankHinge Health, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HNGE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HNGE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HNGE
Jul 30, 2026▼ -0.5%today
Study finds Hinge Health significantly lowers fall risk for adults aged 65+
Hinge Health, Inc. announced a study demonstrating a significant decrease in fall risk among adults aged 65 and older. The research revealed that participants using Hinge Health experienced 37% fewer falls and a 57% reduction in emergency room visits compared to a control group. This study highlights the effectiveness of Hinge Health's approach in improving safety for older adults.
Read more →-HNGE
Jul 6, 2026Hinge Health to announce second quarter 2026 financial results on August 4, 2026
Hinge Health is scheduled to announce its financial results for the second quarter of 2026 on August 4, 2026. The announcement is expected to provide insights into the company's performance during this period. Details regarding the financial results will likely be shared in a press release or during a conference call.
Read more →-HNGE
Jun 10, 2026Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform
Hinge Health has expanded its HingeSelect platform to include surgical options, enhancing its integrated musculoskeletal care offerings. This development aims to provide comprehensive care solutions for patients. The addition signifies Hinge Health's commitment to improving patient outcomes through a more holistic approach to musculoskeletal health.
Read more →-HNGE
Jun 9, 2026Hinge Health hosts its first Investor Day and raises guidance
Hinge Health recently hosted its inaugural Investor Day, where it provided updates on its business performance and future outlook. The company raised its guidance, indicating a positive trajectory in its operations. However, specific details regarding the financial implications were not disclosed in the article.
Read more →-HNGE
Jun 3, 2026Hinge Health proven to deliver 3.0x ROI with the largest study of its kind
Hinge Health has conducted the largest study of its kind, demonstrating a 3.0x return on investment (ROI). The details of the study and its implications for the company's future performance are not provided in the article. The findings may influence stakeholders' perception of Hinge Health's value in the market.
Read more →-HNGE
May 5, 2026Hinge Health reports record first quarter 2026 financial results
Hinge Health has announced its financial results for the first quarter of 2026, reporting record figures. The announcement highlights the company's growth and performance during this period. However, specific financial details and metrics were not provided in the article.
Read more →-HNGE
Apr 29, 2026Hinge Health launches comprehensive Migraine Care Program
Hinge Health has launched a new Migraine Care Program aimed at providing drug-free pain relief and personalized management for migraine sufferers. The program utilizes the FDA-cleared Enso device, which offers rapid pain relief, alongside AI-powered insights for trigger management. With a focus on proactive prevention through exercise therapy, the program is set to roll out in May 2026 and has already gained significant employer interest.
Read more →-HNGE
Feb 10, 2026Hinge Health reports fourth quarter and full year 2025 financial results San Francisco, California
Hinge Health reported impressive financial results for Q4 and full year 2025, achieving record revenue of $587.9 million, a 51% increase from the previous year. The company also saw substantial growth in cash flow, with free cash flow rising by 297%. Despite a noted increase in GAAP losses from operations, Hinge Health's positive future guidance signals confidence in continued growth and operational automation. The announcement reflects strong momentum within the digital musculoskeletal care market.
Read more →-HNGE
Nov 12, 2025Hinge Health announces $250 million share repurchase program San Francisco, California –
Hinge Health, Inc. (NYSE: HNGE) has announced a $250 million share repurchase program approved by its board of directors. The company has shown strong financial performance, generating $108 million in cash from operations in the first three quarters of 2025 and maintaining nearly $500 million in cash and investments. Hinge Health aims to balance share repurchases with continued investment in growth and improving member outcomes, leveraging its AI-powered care model and enhancing operational efficiency.
Read more →-HNGE
Nov 4, 2025▲ +6.2%on this news
Hinge Health reports third quarter 2025 financial results San Francisco, California –
Hinge Health reported strong financial results for Q3 2025, with revenue growth of 53% year-over-year reaching $154.2 million. They surpassed 1.5 million lifetime members and generated record free cash flow of $81.3 million. However, the company experienced an increase in GAAP loss from operations, amounting to $6.1 million. Hinge Health also provided guidance for Q4 2025 and raised their full year revenue expectations, reflecting a positive outlook amidst rising healthcare costs.
Read more →-HNGE
Aug 5, 2025Hinge Health Reports Second Quarter 2025 Financial Results San Francisco, California –
Hinge Health, Inc. (NYSE: HNGE) reported impressive financial results for Q2 2025, showcasing a 55% increase in revenue to $139.1 million. Coupled with a rise in clients by 32% to 2,359, the company's operational performance highlighted its growing acceptance in the market. However, the company recorded a significant GAAP loss driven by stock-based compensation, and its gross margins declined slightly year-over-year. Expectations for the third quarter suggest continued growth, with projected revenues between $141 million and $143 million.
Read more →Competitive Position
How HNGE ranks across every disease it competes inCompetitive Position is a premium feature
See how HNGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial